GREY:IPHAF - Post by User
Post by
wrongturnon Jan 25, 2007 11:39pm
3563 Views
Post# 12095920
Fools rush in..
Fools rush in..Personally, I believe the company needs to be able to carry itself, which is what it did yesterday. IMO there is a high risk that Roche may back out of the transplantation deal and Roche, IMO will not be the suitor for psoriasis. However, if Roche does opt back in for transplantation, it would make for timely payment to complete psoriasis.....possibly alone.
That's the good news. The bad news is that many of us have an ACB over $2 and some over $3. Anybody joining this ship 3 to 7 years ago are paying heavily. But then again, we're not Stressgen either.
Overall, I'm not as excited about this stock as I was 6 years ago.
To any new investors, wait to see what happens with Roche before any purchase. If Roche does not opt back in after the completion of IIb, you may have an opportunity to pick-up ISA for less than $1. As a current investor, I'm hoping ISA would forsee this possibility and would have made arrangements with another large pharma in such an event. But then again, may be these guys will try to carry transplantation on their own?